Gilead Sciences, Inc. $GILD Shares Acquired by D.A. Davidson & CO.

D.A. Davidson & CO. lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.8% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 77,509 shares of the biopharmaceutical company’s stock after purchasing an additional 10,586 shares during the quarter. D.A. Davidson & CO.’s holdings in Gilead Sciences were worth $10,803,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences during the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC grew its stake in Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 85 shares during the period. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter worth $26,000. Wealth Preservation Advisors LLC increased its position in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new position in shares of Gilead Sciences in the 4th quarter valued at $28,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on GILD. The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Royal Bank Of Canada lowered their price target on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a report on Tuesday, July 7th. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Daiwa Securities Group reduced their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 19th. Finally, Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research report on Wednesday, May 20th. Twenty-six investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $159.04.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $136.30 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The firm has a 50-day moving average of $129.67 and a two-hundred day moving average of $135.23. The stock has a market cap of $169.23 billion, a P/E ratio of 18.57 and a beta of 0.32. Gilead Sciences, Inc. has a 1-year low of $107.75 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period last year, the firm earned $1.81 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. The trade was a 1.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00. Following the completion of the transaction, the chief executive officer directly owned 607,133 shares in the company, valued at approximately $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 77,000 shares of company stock worth $9,978,740 in the last three months. 0.30% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.